Vanda Pharmaceuticals (VNDA) Cost of Revenue (2010 - 2026)

Vanda Pharmaceuticals has disclosed Cost of Revenue across 14 years of filings, most recently posting $3.2 million for Q1 2026.

• Cost of Revenue for Q1 2026 came in at $3.2 million, down 10.28% year-over-year; the trailing twelve-month figure through Mar 2026 was $12.7 million (up 11.29% YoY), and the FY2025 annual result was $13.0 million, up 15.29% from the prior year.
• Cost of Revenue came in at $3.2 million for Q1 2026 at Vanda Pharmaceuticals, down from $3.8 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $6.3 million in Q3 2022 to a low of $2.6 million in Q3 2024.
• The 5-year median for Cost of Revenue is $3.5 million (2023), against an average of $3.9 million.
• Across the five-year window, Cost of Revenue tumbled 51.53% in 2023 and surged 47.99% in 2025, its largest moves.
• Vanda Pharmaceuticals' Cost of Revenue stood at $6.2 million in 2022, then slumped by 44.53% to $3.5 million in 2023, then fell by 25.14% to $2.6 million in 2024, then soared by 47.99% to $3.8 million in 2025, then declined by 17.58% to $3.2 million in 2026.
• The last three Cost of Revenue figures came in at $3.2 million (Q1 2026), $3.8 million (Q4 2025), and $3.0 million (Q3 2025), per Business Quant data.